Commentary, Jrgm Vol: 13 Issue: 5

Synthetic Biology in Cell Engineering: Reprogramming Cells for Therapeutic Use.

Carl Hill^*

Riley Hospital for Children, Indiana University, USA

*Corresponding Author: Carl Hill
Riley Hospital for Children, Indiana University, USA
E-mail: prins.chantal@van.nl

Received: 02-Sep-2024, Manuscript No. JRGM-24-148118
Editor assigned: 03-Sep-2024, PreQC No. JRGM-24-148118 (PQ)
Reviewed: 17-Sep-2024, QC No. JRGM-24-148118
Revised: 23-Sep-2024, Manuscript No. JRGM-24-148118 (R)
Published: 27-Sep-2024, DOI:10.4172/2325-9620.1000328

Citation: Hill C (2024) Synthetic Biology in Cell Engineering: Reprogramming Cells for Therapeutic Use. J Regen Med 13:5.

Copyright: © 2024 Hill C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Introduction

Synthetic biology, an interdisciplinary field that merges biology with engineering principles, has revolutionized the realm of cell engineering. By enabling the reprogramming of cellular functions, synthetic biology offers unprecedented opportunities for therapeutic applications, including the development of new treatments for genetic disorders, cancer, and regenerative medicine. This article explores the fundamental concepts of synthetic biology in cell engineering and its potential in therapeutic use [1].

Synthetic biology involves the design and construction of novel biological parts, devices, and systems, or the redesign of existing natural biological systems. The foundation lies in the ability to manipulate genetic material, allowing scientists to create standardized biological components, such as genetic circuits, that can be integrated into cells to perform desired functions. This approach differs from traditional genetic engineering, which primarily involves gene modification, as synthetic biology aims to create entirely new functionalities in living organisms [2].

Cell engineering through synthetic biology focuses on reprogramming cells to perform specific tasks, such as producing therapeutic proteins, repairing damaged tissues, or attacking cancer cells. The concept of cellular reprogramming is grounded in the ability to alter the cell's gene expression, thereby changing its phenotype. For therapeutic purposes, cells can be re-engineered to respond to environmental cues, secrete drugs, or differentiate into other cell types that can replace or repair damaged tissues [3].

A critical aspect of synthetic biology is the creation of gene circuits that function like electrical circuits, where genetic components interact in a controlled manner to regulate cellular behavior. These circuits can be designed to trigger specific cellular responses, such as the production of insulin in response to glucose levels, or to activate immune cells to target specific cancer cells. Programmable cells are key to therapeutic interventions, as they can be engineered to execute complex tasks, reducing the need for external drug delivery [4].

One of the most promising areas of synthetic biology in cell engineering is cancer therapy. By reprogramming immune cells, such as T-cells, using synthetic biology tools, researchers can create chimeric antigen receptor (CAR) T-cells. These CAR T-cells are designed to recognize and attack cancer cells, offering a targeted approach to treatment. Several CAR T-cell therapies have already been approved for treating blood cancers, demonstrating the therapeutic potential of synthetic biology in cell-based cancer therapies [5].

Synthetic biology also plays a significant role in regenerative medicine, where it is used to engineer cells for tissue repair and regeneration. By reprogramming stem cells, scientists can guide their differentiation into specific cell types, such as neurons, muscle cells, or hepatocytes, which can then be used to repair damaged tissues. This technology holds the potential to treat degenerative diseases like Parkinson’s, Alzheimer’s, and heart disease, where tissue loss is a significant concern [6].

The advent of CRISPR-Cas9 technology has further expanded the capabilities of synthetic biology in cell engineering. CRISPR allows for precise gene editing, enabling scientists to introduce, delete, or modify specific genes within a cell. This precision is crucial for therapeutic applications, particularly for treating genetic disorders. By correcting faulty genes, CRISPR-based therapies have the potential to provide long-term solutions for diseases such as cystic fibrosis, sickle cell anemia, and muscular dystrophy [7].

While synthetic biology holds immense promise, it also raises important safety and ethical concerns. Reprogramming cells for therapeutic use must ensure that the engineered cells do not cause unintended consequences, such as off-target effects or uncontrolled cell proliferation, which could lead to tumor formation. Furthermore, ethical considerations regarding the manipulation of human cells, particularly in germline editing, must be carefully weighed to avoid unintended societal and genetic impacts [8].

Despite significant advances, translating synthetic biology from the lab to the clinic poses several challenges. These include ensuring the scalability of engineered cells, maintaining the stability and functionality of synthetic gene circuits in the human body, and navigating complex regulatory pathways. Developing robust safety protocols and overcoming immunogenicity—the body’s rejection of foreign cells—are critical hurdles that must be addressed before synthetic biology-based therapies can become mainstream treatments [9].

The future of synthetic biology in cell engineering is promising, with ongoing research focused on developing more sophisticated gene circuits, improving the precision of gene editing tools like CRISPR, and creating cells that can self-regulate and adapt to changing environments. Innovations such as synthetic biocomputers, which use biological molecules to process information inside cells, may allow for even more complex therapeutic interventions [10].

Conclusion

Synthetic biology is transforming the landscape of cell engineering, offering new possibilities for therapeutic use by reprogramming cells to perform targeted functions. From cancer immunotherapy to regenerative medicine, the potential applications of this technology are vast. However, challenges in safety, scalability, and ethical concerns must be addressed as the field continues to evolve. As advancements in gene editing, cell programming, and synthetic biocomputing progress, synthetic biology will likely play a central role in the future of medicine, providing innovative solutions to previously untreatable conditions.

References

1. Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr; 26: 43–49.

Indexed at, Google Scholar, Cross Ref

2. Bluestone JA, Trotta E, Xu D (2015) The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets; 19(8):1091-103.

Indexed at, Google Scholar, Cross Ref

3. Cella F, Wroblewska L, Weiss R, Siciliano V (2018). Engineering protein-protein devices for multilayered regulation of mRNA translation using orthogonal proteases in mammalian cells. Nat Commun; 9(1):4392.

Indexed at, Google Scholar, Cross Ref

4. Cho JH, Collins JJ, Wong WW (2018) Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell;173(6):1426-38.

Indexed at, Google Scholar, Cross Ref

5. Harris DT, Kranz DM (2016). Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci; 37(3):220-30.

Indexed at, Google Scholar, Cross Ref

6. Johnson LA, June CH (2017). Driving gene-engineered T cell immunotherapy of cancer. Cell Res; 27(1):38-58.

Indexed at, Google Scholar, Cross Ref

7. Kitada T, DiAndreth B, Teague B, Weiss R (2018) Programming gene and engineered-cell therapies with synthetic biology. Science; 359(6376):eaad1067.

Indexed at, Google Scholar, Cross Ref

8. Kojima R, Scheller L, Fussenegger M (2018)  Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation. Nat Chem Biol 2018; 14(1):42-9.

Indexed at, Google Scholar, Cross Ref

9. Liu Y, Bai P, Woischnig AK, Charpin-El Hamri G, Ye H, et al. (2018). Immunomimetic Designer Cells Protect Mice from MRSA Infection. Cell 2018;174(2):259-70.

Indexed at, Google Scholar, Cross Ref

10. Marshall HT, Djamgoz MB (2018) Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol 2018;8:315.

Indexed at, Google Scholar, Cross Ref